Travere Therapeutics, Inc. · NASDAQ:TVTX
Inrig Jula sold 44,674 Travere Therapeutics, Inc. shares (Form 4)
Traded Sep 15, 2026 · Filed Sep 17, 2026
On Sep 15, 2026, Inrig Jula (EVP, Head of R&D & CMO) sold 44,674 Travere Therapeutics, Inc. shares at an average US$62.34 for US$2.79M under a trading plan, leaving 100,491 shares. Filed Sep 17, 2026 (Form 4).
- Sold
- 44,674 shares
- Price
- US$62.34 average (US$62.02 to US$65.31)
- Value
- US$2.79M
- Holding after
- 100,491 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- EVP, Head of R&D & CMO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Common Stock | Option exercise | 32,395 | US$8.93 | 145,165 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 25,390 | US$62.02 | 119,775 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 17,284 | US$62.62 | 102,491 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 1,600 | US$63.69 | 100,891 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 400 | US$65.31 | 100,491 | Direct |
Source
Related
- Travere Therapeutics, Inc.
- Inrig Jula
- Travere Therapeutics, Inc. shareholders
- Form 4 · Inrig Jula · Jun 22, 2026
- Form 4 · Inrig Jula · May 6, 2026
- Form 4 · Inrig Jula · Apr 15, 2026
- Form 4 · Dube Eric M · Oct 19, 2026
- Form 4 · Heerma Peter · Sep 17, 2026
- Form 4 · Dube Eric M · Sep 17, 2026
- Form 4 · Rote William E. · Sep 17, 2026
- Schedule 13G/A · Armistice Capital, LLC · Aug 14, 2026